research 0475 High-dose UVA-1 therapy improves patient-reported outcomes and clinical scores in patients with sclerosing skin disease
High-dose UVA-1 therapy improves symptoms and skin condition in sclerosing skin disease.
Search
for
Sort by
Research
540-570 / 1000+ resultsresearch Characterizing Lipid Changes and Use of Lipid-Lowering Medications in Patients With Alopecia Areata Treated With Baricitinib: Integrated Results From the BRAVE-AA1 and -AA2 Clinical Trials
Baricitinib slightly increased cholesterol levels in alopecia areata patients, but these changes were manageable.
research Alopecia areata clinical trial enrollment and retention outcome factors among underrepresented ethnic and racial groups: A cross-sectional study
Clinical trials for alopecia areata need better inclusion and retention of patients of color.
research Evaluating the safety profile of α-1 blockers, 5α-reductase inhibitors, and PDE5I for BPH: a disproportionality analysis of real-world adverse events based on FDA adverse event reporting system (FAERS)
PDE5 inhibitors cause earlier adverse events in BPH treatment, requiring careful monitoring.
research Oral minoxidil 2.5 mg versus 5 mg for treatment of male androgenetic alopecia: a double-blind randomized clinical trial
The 5 mg dose of oral minoxidil is not more effective than the 2.5 mg dose for treating male hair loss.
research Low-Level Light Therapy for Androgenetic Alopecia: A 24-Week, Randomized, Double-Blind, Sham Device–Controlled Multicenter Trial
Low-level light therapy safely improves hair growth and thickness for androgenetic alopecia.
research CUTANEOUS T-CELL LYMPHOMA
The document concludes that DAB389-IL2 is promising for treating refractory cutaneous T-cell lymphoma, but more research is needed on its effectiveness and side effect management.
research Correction to: Efficacy assessment for low‑level laser therapy in the treatment of androgenetic alopecia: a real‑world study on 1383 patients
research Preclinical Development and Phase I Study of ZSYY001 , a Polymeric Micellar Paclitaxel for Advanced Solid Tumor
ZSYY001 is safe, well-tolerated, and shows promise for treating advanced solid tumors.
research Cervi Parvum Cornu complex for men with lower urinary tract symptoms: a multicenter, randomized, double-blind, placebo-controlled trial
Cervi Parvum Cornu complex improved urinary symptoms in men without major side effects.
research Managing hyperglycemia and rash associated with alpelisib: expert consensus recommendations using the Delphi technique
Experts agree on how to manage sugar levels and skin reactions in patients taking the cancer drug alpelisib.
research Low-level Laser Therapy with Novel Array of Light Source and Individualized Program for Treatment of Androgenetic Alopecia: A 16-week, Randomized, Double-blind, Sham Device-controlled Study
The laser therapy device effectively increased hair growth in people with androgenetic alopecia.
research American College of Clinical Pharmacology Twenty‐Second Annual Meeting November 1–3, 1993 Boston, Massachusetts
research Reduced cardiotoxicity and comparable efficacy in a phase IIItrial of pegylated liposomal doxorubicin HCl(CAELYX™/Doxil®) versus conventional doxorubicin forfirst-line treatment of metastatic breast cancer
Pegylated liposomal doxorubicin is as effective as conventional doxorubicin but causes fewer heart problems and side effects.
research Table 1_Longitudinal clinical course, treatment outcomes, and relapse patterns in alopecia areata: a prospective cohort study.docx
Baseline severity, disease activity, and relapse history are key to predicting response and recurrence in alopecia areata.
research 170 Forecasting Phase 3 Dose-Response for Abrocitinib, an Oral Janus Kinase 1 Selective Inhibitor, Using Investigator’s Global Assessment and Eczema Area and Severity Index
Abrocitinib at 100 mg and 200 mg daily may significantly improve moderate-to-severe atopic dermatitis in patients 12 years and older.
research Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in patients with alopecia areata: efficacy and safety results of a phase II, multicenter, randomized, double-blinded, placebo-controlled trial
Deucravacitinib did not significantly improve hair regrowth in alopecia areata patients.
research Randomized Therapeutic trial for patients with Alopecia Areata .
Topical minoxidil, intralesional steroids, and cryotherapy significantly improve alopecia areata.
research P718 Observational real-world evidence on the efficacy and safety of Janus Kinase inhibitors (JAKi) in the treatment of moderate to severe Active Ulcerative Colitis (UC)
Janus Kinase inhibitors are effective and have an acceptable safety profile for treating moderate to severe Ulcerative Colitis.
research Influence of Concurrent and Adjuvant Temozolomide on Health-Related Quality of Life of Patients with Grade III Gliomas: A Secondary Analysis of a Randomized Clinical Trial (KNOG-1101 Study)
Temozolomide improves survival in grade III glioma patients without harming quality of life.
research Coexistence of angiolymphoid hyperplasia with eosinophilia and pulmonary neoplasia
A man with both skin lesions and lung cancer improved quickly with chemotherapy, suggesting the skin condition might be a reaction to immune system injury.
research Therapeutic Burden as Predictor of Response to Baricitinib for Alopecia Areata in Real Life: Prospective Study
Patients with fewer past treatments for alopecia areata respond better to baricitinib.
research Increased risk of hair loss with GLP-1 receptor agonists: A real-world multicenter TrinetX cohort study
research Retrospective cohort study of CDK4/6-inhibitor-induced alopecia in breast cancer patients
research Seizure control and side-effect profile after switching adult epileptic patients from standard to extended-release divalproex sodium
Switching to extended-release divalproex sodium improved patient-reported tremor but did not change seizure frequency or most side effects.
research This Month in Clinical Urology
New treatments and diagnostic methods for urological conditions show promise, but some lack sufficient accuracy for clinical use.
research BH06 (P075) A randomized controlled trial comparing the efficacy and safety of oral tofacitinib vs. methotrexate in moderate-to-severe alopecia areata
Tofacitinib is more effective than methotrexate for treating moderate-to-severe alopecia areata.
research Safety and efficacy of actinic keratoses reduction with a 3 day application of ingenol disoxate field treatment to the face, chest and balding scalp
The treatment increased hair follicle counts and is potentially effective for male hair loss without serious side effects.
research A phase I safety study of topical calcitriol (BPM31543) for the prevention of chemotherapy-induced alopecia (CIA): Final study results
Topical calcitriol (BPM31543) is safe for preventing hair loss from chemotherapy and shows some effectiveness.
research Comparison between low-dose chemotherapy and surgery for the treatment of extremity-associated solitary bone lesions in children with Langerhans cell histiocytosis in South China: A case-control study
Low-dose chemotherapy is safer, more effective, and cost-effective than surgery for treating bone lesions in children.